$PVCT's 10-Q: Q1 2013

Provectus released its 10-Q filing for Q1 2013 today. See here. Some thoughts...

#1. Quarter-over-quarter ("QoQ") -- Q1 2013-over-Q4 2012 -- monthly cash expenditure appears to have decreased by about 11%. Provectus' quarterly and annual filings since and including Q1 2012, the company appears to suggest an average monthly cash burn of approximately $950K (with a standard deviation of $133K).

#2.  Management expanded on their Q4 2012 MD&A statement via the 10-K of...

"We are seeking to improve our cash flow through both the licensure of PH-10 on the basis of our Phase 2 atopic dermatitis and psoriasis results, and the geographic licensure of PV-10 on the basis of our Phase 2 metastatic melanoma and Phase 1 liver results in certain areas of the world, as well as pursuing a strategic investment strategy, including equity sales to potential pharmaceutical and or biotech partners, and continuing with the majority stake asset sale and licensure of our OTC products as well as other non-core assets. The geographic areas of interest for PV-10 principally include China, India, Japan and Middle East and North Africa (MENA). We are also considering the global licensure of PV-10 as well since it has come to our attention that this is of interest to potential partners."

...with the following in their Q1 2013 statement:

"We are seeking to improve our cash flow through both the licensure of PH-10 on the basis of our Phase 2 atopic dermatitis and psoriasis results, and primarily the geographic licensure of PV-10 on the basis of our Phase 2 metastatic melanoma and Phase 1 liver results in certain areas of the world, as well as pursuing a strategic investment strategy, including equity sales to potential pharmaceutical and/or biotech partners. In addition, the data now available from Moffitt Cancer Center in Tampa, Florida has been particularly helpful in supporting our development plans with both the FDA and prospective partners. The geographic areas of interest for PV-10 principally include China, India, Japan and Middle East and North Africa (MENA). We are also considering the global licensure of PV-10 as well since it has come to our attention that this is of interest to potential partners. We also expect to continue with the majority stake asset sale and licensure of our non-core assets. However, the primary objective of ours is to strategically monetize the core value of PV-10 and PH-10 through various transactions, leveraging value creation up to and including an appropriate Merger and Acquisition transaction."

primarily suggests to me management is prioritizing a series or string of regional/other licenses (e.g., China, India, Japan, PH-10) to boost company valuation towards their end game valuation expectation.

In addition... suggests repetition of the importance of Moffitt to what the FDA and Big Pharma needed regarding PV-10's systemic benefit and potential, and that is very likely crucial to securing and most assuredly dispositive of receiving breakthrough therapy designation for PV-10 for recurrent and metastatic melanoma.

However... suggests focus on smartly, intelligently and thoughtfully protecting valuation to, again, achievement management's end game valuation expectation. Noteworthy to me was the inclusion of the verbiage "an appropriate Merger and Acquisition transaction."

#3.  Noteworthy to me was the issuance of 1.92MM warrants to consultants in exchange for services in the quarter. To whom and why?